TAEST-16001 Drug Asset Due Diligence Report 2026

This TAEST-16001 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether TAEST-16001 can convert its TCR-T Cell therapy profile and NY-ESO-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	TAEST-16001 (query alias: TAEST-16001)
Modality / target	TCR-T Cell therapy; NY-ESO-1; NY-ESO-1 inhibitors
Highest global status	Phase 2
Originator	Xiangxue Pharmaceutical Co., Ltd.
Active developers	Guangdong Xiangxue Precision Medical Technology Co., Ltd., Xiangxue Life Science Technology (Guangdong) Co., Ltd., Xiangxue Pharmaceutical Co., Ltd.

The MCP disease footprint includes Locally Advanced Soft Tissue Sarcoma, Advanced Malignant Solid Neoplasm, Non-Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20262246	Phase 2	Recruiting	62	Primary endpoint not disclosed in English source
NCT05549921	Phase 2	Terminated	8	Primary endpoint not disclosed in English source
CTR20221312	Phase 2	Active, not recruiting	56	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.

Phase 2; n=8; evaluation: Positive. Reported fields: Adverse Event: decreased WBC count = n=7

Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma

Phase 1; n=12; evaluation: Positive. Reported fields: ORR = 41.7 %

Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A*02:01 patients with advanced soft tissue sarcoma.

Phase 1; n=12; evaluation: Positive. Reported fields: DLT = 0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

TAEST-16001 addresses Locally Advanced Soft Tissue Sarcoma, Advanced Malignant Solid Neoplasm, Non-Small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—TCR-T Cell therapy—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 13 matched transaction record(s) under the scope “target-level comparable: NY-ESO-1.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: NY-ESO-1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-07-28	US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel	Phase 2	US$55.0M upfront; US$30.0M milestones
2025-01-16	AGC Biologics’ Milan Site to Prepare Lentiviral Vector Commercial Manufacturing for Adaptimmune’s Lete-Cel Product	Phase 2	Financial terms not disclosed
2023-10-25	AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Cytokine-release syndrome, neurotoxicity, infection, and treatment logistics
Durability of response and antigen escape
Manufacturing scalability, release testing, and site readiness

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO